cancer drugs

See the following -

Could An Open-Access Database Speed Up Drug Development?

Summer Allen | AAAS Member Central | October 6, 2014

A recent study finds a significant logjam in the development of new drugs at the discovery and early preclinical phases. Could the creation of an open-source translational research database help solve the problem?...

Read More »

Is Shkreli the Exception, or the Norm, in Big Pharma?

I didn't want to write about pharmaceutical companies.  They get enough bad press, and adding to it almost seems like piling on.  If Valeant is the poster company for outrage about drug pricing, it's less because what they are doing is unusual than it is because we suspect they are the norm. Honestly, I wanted to discuss McDonald's turning their Happy Meals boxes into VR headsets --I'm not making that up -- but, gosh darn it, it's almost like the pharmaceutical companies are daring me to talk about them.  So I will.

Read More »

Merck To Bristol-Myers Face Threats On India Patents (Correct)

Ketaki Gokhale | Bloomberg Businessweek | January 28, 2014

Pharmaceutical companies from Merck & Co. (MRK:US) to Bristol-Myers Squibb Co. (BMY:US) face fresh threats to protecting their patents in India as a government-appointed panel prepares to evaluate more drugs for local makers to copy.  The panel is looking beyond the cancer treatments it studied last year to areas such as HIV and diabetes, according to two people with knowledge of the matter, who asked not to be identified because the discussions are private.

Read More »

On the Financial Conflicts of Interests of Medical Societies and Rising Drug Prices

The notion that health care prices are high and are rising continuously in the US should hardly be novel...We first posted about high drug prices in July, 2005, with the example of BilDil...But only a few days later we noted that three cancer costs had yearly costs in the five figures, and one, Erbitux, cost as much as $100,000.  Most amazingly we noted that Thalidomid was priced at $25,000  a year...Since then, the ridiculously high prices of many tests and treatments, but most notably new drugs and devices, has been so widely covered, our discussion has been limited to special cases.,,

Read More »